Summit Therapeutics (SMMT) Other financing activities (2019 - 2024)

Summit Therapeutics has reported Other financing activities for 6 years, with the latest figure at $1.2 million in Q4 2024.

• For the quarter ending Q4 2024, Other financing activities changed N/A year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2024 stood at $1.2 million (up 92.25% YoY), and the FY2023 full-year result was $619000.0, up 457.66% from the prior year.
• Other financing activities for Q4 2024 stood at $1.2 million, up from $80000.0 in the prior quarter.
• The five-year high for Other financing activities was $1.2 million in Q4 2024, with the low at -$41000.0 in Q4 2021.
• Historically, Other financing activities has averaged $290285.7 across 5 years, with a median of $105000.0 in 2021.
• Annual changes were most pronounced in 2021 — Other financing activities sank 185.42% — and 2022, when it advanced 5.71%.
• Summit Therapeutics' Other financing activities stood at $48000.0 in 2020, then plunged by 185.42% to -$41000.0 in 2021, then soared by 370.73% to $111000.0 in 2022, then retreated by 27.93% to $80000.0 in 2023, then soared by 1387.5% to $1.2 million in 2024.
• The last three Other financing activities figures came in at $1.2 million (Q4 2024), $80000.0 (Q2 2023), and $539000.0 (Q1 2023), per Business Quant data.